{Reference Type}: Case Reports
{Title}: Durvalumab-associated limbal stem cell deficiency and secondary corneal perforation.
{Author}: Schumaier NP;Heidemann DG;Gupta C;
{Journal}: Am J Ophthalmol Case Rep
{Volume}: 35
{Issue}: 0
{Year}: 2024 Sep
暂无{DOI}: 10.1016/j.ajoc.2024.102074
{Abstract}: <B>UNASSIGNED: </B>We report a patient with bilateral limbal stem cell deficiency (LSCD) like clinical manifestations and secondary corneal perforation presumably induced by durvalumab following its use for the treatment of non-small cell lung carcinoma.<BR><B>UNASSIGNED: </B>A 65-year-old male diagnosed with non-small cell lung carcinoma was treated with monthly durvalumab infusions. Two months after starting durvalumab, the patient was found to have bilateral severe keratoconjunctivitis and LSCD-like clinical findings. Despite topical management and oral prednisone for presumed ocular cicatricial pemphigoid, the patient continued to worsen clinically. The patient was transferred to our institution about one year later with persistent inflammation. The patient eventually developed a corneal perforation of the left eye, which required the application of cyanoacrylic tissue adhesive. Due to the lack of response to oral prednisone, durvalumab was discontinued with the approval of the patient's oncologist. Several months following the discontinuation of durvalumab, the conjunctival inflammation subsided, and corneal epithelial breakdown and ulceration resolved.<BR><B>UNASSIGNED: </B>We report an association between durvalumab and the development of bilateral LSCD-like clinical findings with subsequent corneal perforation. We hope this case reinforces the importance of routine ophthalmologic follow-up after starting any cancer treatment, especially in patients with symptoms and signs suggesting ocular surface disease or inflammation.